Protocol
12-170
Full Title
A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma
Purpose
Despite currently available treatments for lymphoma and multiple myeloma, many patients experience a relapse of their disease. Doctors are therefore seeking more effective therapies. The purpose of this study is to evaluate the combination of two currently available therapies — romidepsin and lenalidomide — in patients with lymphoma or multiple myeloma that has returned or persisted despite prior therapy.
Romidepsin is a drug that is approved to treat cutaneous T-cell lymphoma in patients who have already received a regimen of prior therapy. Lenalidomide is approved for treating multiple myeloma and myelodysplastic syndromes. This study marks the first time these two drugs will be evaluated together.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have lymphoma or multiple myeloma that has returned or persisted despite one regimen of prior chemotherapy.
- At least 3 weeks must have passed since completion of prior chemotherapy and 2 weeks since radiation therapy, hormonal therapy, or surgery and entry into the study.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.
Disease(s)
Hematology: Multiple Myeloma
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
Related Diseases
